BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 29689531)

  • 1. Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.
    Rastrojo A; García-Hernández R; Vargas P; Camacho E; Corvo L; Imamura H; Dujardin JC; Castanys S; Aguado B; Gamarro F; Requena JM
    Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):246-264. PubMed ID: 29689531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.
    Hendrickx S; Boulet G; Mondelaers A; Dujardin JC; Rijal S; Lachaud L; Cos P; Delputte P; Maes L
    Parasitol Res; 2014 May; 113(5):1875-81. PubMed ID: 24615359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and Metabolomic Polymorphism among Experimentally Selected Paromomycin-Resistant Leishmania donovani Strains.
    Shaw CD; Imamura H; Downing T; Blackburn G; Westrop GD; Cotton JA; Berriman M; Sanders M; Rijal S; Coombs GH; Dujardin JC; Carter KC
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
    Hendrickx S; Mondelaers A; Eberhardt E; Delputte P; Cos P; Maes L
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4714-8. PubMed ID: 26014955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani.
    Verma A; Bhandari V; Deep DK; Sundar S; Dujardin JC; Singh R; Salotra P
    Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):370-377. PubMed ID: 29035735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput Cos-Seq screen with intracellular Leishmania infantum for the discovery of novel drug-resistance mechanisms.
    Fernandez-Prada C; Sharma M; Plourde M; Bresson E; Roy G; Leprohon P; Ouellette M
    Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):165-173. PubMed ID: 29602064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Preadaptation to Antimony Resistance in Leishmania donovani on the Indian Subcontinent.
    Dumetz F; Cuypers B; Imamura H; Zander D; D'Haenens E; Maes I; Domagalska MA; Clos J; Dujardin JC; De Muylder G
    mSphere; 2018 Apr; 3(2):. PubMed ID: 29669889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol.
    Hendrickx S; Inocêncio da Luz RA; Bhandari V; Kuypers K; Shaw CD; Lonchamp J; Salotra P; Carter K; Sundar S; Rijal S; Dujardin JC; Cos P; Maes L
    PLoS Negl Trop Dis; 2012; 6(5):e1664. PubMed ID: 22666513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative transcriptomic analysis of antimony resistant and susceptible Leishmania infantum lines.
    Andrade JM; Gonçalves LO; Liarte DB; Lima DA; Guimarães FG; de Melo Resende D; Santi AMM; de Oliveira LM; Velloso JPL; Delfino RG; Pescher P; Späth GF; Ruiz JC; Murta SMF
    Parasit Vectors; 2020 Nov; 13(1):600. PubMed ID: 33256787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.
    Shaw CD; Lonchamp J; Downing T; Imamura H; Freeman TM; Cotton JA; Sanders M; Blackburn G; Dujardin JC; Rijal S; Khanal B; Illingworth CJ; Coombs GH; Carter KC
    Mol Microbiol; 2016 Mar; 99(6):1134-48. PubMed ID: 26713880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.
    Hendrickx S; Beyers J; Mondelaers A; Eberhardt E; Lachaud L; Delputte P; Cos P; Maes L
    J Antimicrob Chemother; 2016 Jul; 71(7):1914-21. PubMed ID: 27084919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes.
    Maarouf M; Adeline MT; Solignac M; Vautrin D; Robert-Gero M
    Parasite; 1998 Jun; 5(2):167-73. PubMed ID: 9754313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.
    Mondelaers A; Sanchez-Cañete MP; Hendrickx S; Eberhardt E; Garcia-Hernandez R; Lachaud L; Cotton J; Sanders M; Cuypers B; Imamura H; Dujardin JC; Delputte P; Cos P; Caljon G; Gamarro F; Castanys S; Maes L
    PLoS One; 2016; 11(4):e0154101. PubMed ID: 27123924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
    Hendrickx S; Van den Kerkhof M; Mabille D; Cos P; Delputte P; Maes L; Caljon G
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005620. PubMed ID: 28505185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani.
    Bhandari V; Sundar S; Dujardin JC; Salotra P
    Antimicrob Agents Chemother; 2014 May; 58(5):2580-5. PubMed ID: 24550335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani.
    Vacchina P; Norris-Mullins B; Carlson ES; Morales MA
    Parasit Vectors; 2016 Dec; 9(1):621. PubMed ID: 27906059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania.
    Moreira W; Leprohon P; Ouellette M
    Cell Death Dis; 2011 Sep; 2(9):e201. PubMed ID: 21881603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series.
    Van den Kerkhof M; Mabille D; Chatelain E; Mowbray CE; Braillard S; Hendrickx S; Maes L; Caljon G
    Int J Parasitol Drugs Drug Resist; 2018 Apr; 8(1):81-86. PubMed ID: 29425734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani.
    Seifert K; Munday J; Syeda T; Croft SL
    J Antimicrob Chemother; 2011 Apr; 66(4):850-4. PubMed ID: 21393188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.